Zogenix, Inc. (Zogenix) is a pharmaceutical company, which is engaged in development and commercialization of therapies for people with central nervous system (CNS) disorders. The Company focuses on the areas of pain, epilepsy and schizophrenia. It is engaged in the development of Relday, a product candidate for the treatment of schizophrenia. The Company develops ZX007, an abuse-deterrent tablet formulation of single entity, extended-release hydrocodone. The Company commercializes Sumavel DosePro (sumatriptan injection), a needle-free delivery system. Sumavel DosePro offers the administration of sumatriptan for the acute treatment of migraine and cluster headache. The Company sells Sumavel DosePro to wholesale pharmaceutical distributors, pharmacies and hospitals.